Komodo Health

Overview

Komodo Health is a healthcare data and analytics platform company founded in 2014 by Dr. Arif Nathoo (CEO, Harvard neurobiology/HMS background, seven years at McKinsey) and Web Sun (President, Rutgers/NYU Stern, former Campbell Alliance and Zephyr Health). The founding thesis: pharmaceutical organizations were spending years and tens of millions on bespoke consulting projects to answer patient-journey questions that a well-built, continuously refreshed data platform could answer in minutes.

As of early 2026, Komodo serves more than 200 life sciences and healthcare organizations, including 19 of the top 20 biopharma companies. Core customers include Johnson & Johnson, Merck, Novo Nordisk, Regeneron, Takeda, and Pfizer. Forbes Cloud 100 five consecutive years; TIME World’s Top HealthTech Companies 2025.

Komodo competes in the global RWE solutions market (~$1.3B in 2024, projected $3.7B by 2031 at 13.9% CAGR). Closest competitors: IQVIA, Optum, Veeva Crossix, Flatiron Health (Roche), and Definitive Healthcare.

Services & Capabilities

The Healthcare Map — Core Data Asset

Proprietary de-identified, longitudinal patient-level dataset: 330 million unique patient journeys, 16 million clinical encounters added daily, 160 million closed, linkable lives. Sources: fee-for-service Medicare, Medicare Advantage, commercial claims, Medicaid, EHR, and specialty pharmaceutical data. Differentiated by integration architecture — not a single-source claims feed but multi-payer longitudinal linkage plus specialty datasets through MapEnhance partners (Invitae/GeneDx genomics, PointClickCare EMR, Trio Health/COTA diagnostics, Helix whole-exome genomic data from 500,000+ patients as of January 2025).

Patient linkage uses universal tokenization through a Sentinel layer, enabling proprietary datasets from pharma clients to be linked without exposing identities.

Analytics Platform — MapLab Suite

• MapView: Pre-built dashboards for disease trends, treatment pathways, brand performance
• MapExplorer: No-code cohort building with Definitions Builder
• MapLab Enterprise: Full-environment access for HEOR teams and RWE researchers
• MapAI (2024): NLP assistant accepting plain-language queries for cohort building
• Marmot (August 2025): Healthcare-native AI engine trained on 1M+ active cohorts. Purpose-built for healthcare analytics with auditable outputs, confidence metrics, citations. Demonstrated colorectal cancer disparities analysis across 878,000 patients in ~1 hour vs. weeks. Early adopter: Alnylam Pharmaceuticals.

Pharma Commercial Applications

• Iris: Field sales intelligence — HCP targeting, brand performance, market share
• Pulse: Real-time alert engine (47% increase in script activity, 4x email click rate improvement)
• Drug Projections (2024): Real-time market intelligence on 10,000+ therapies (pharmacy + medical benefit)
• Komodo Patient Insurance / KPI (2024): Payer mix analysis and reimbursement tracking
• Aperture: Medical affairs KOL identification and segmentation

Clinical Trial Analytics

Site selection, patient recruitment, protocol design. Janssen R&D published peer-reviewed validation in PLOS ONE (March 2024) demonstrating ML models trained on Healthcare Map data significantly outperformed baselines for predicting patient enrollment. Covers race/ethnicity data for 265M individuals for enrollment diversity compliance.

HEOR and Regulatory Evidence

250+ peer-reviewed studies at ISPOR 2025. Notable: full-scale epidemiology study supporting FDA evaluation of clozapine REMS program completed in two months (December 2025), typically requiring years via legacy approaches.

Competitive Position

vs. IQVIA

IQVIA is the incumbent market leader ($15B+ revenue vs. Komodo ~$150M ARR estimated). IQVIA’s advantages: global footprint (100+ countries), CRO services, prescriber databases as market standard. Komodo’s claim: self-service platform reduces consulting layer, lowering cost per insight. Komodo is US-only — a material limitation for global pharma teams.

vs. Veeva Crossix

Veeva Crossix dominates pharma marketing analytics (DTC attribution, campaign measurement within CRM); Komodo dominates pharma evidence analytics (HEOR, patient journey, clinical trial site ID). Largely complementary. Veeva’s December 2025 AI Agents surfacing Crossix data into CRM is an integration advantage Komodo cannot easily replicate.

vs. Flatiron Health

Flatiron (Roche subsidiary) is the specialist oncology RWD leader with structured EHR abstraction (~4M oncology records). Komodo’s disadvantage: claims data misses staging, pathology, biomarkers. Komodo’s advantage: breadth (330M patients vs. 4M) across all treatment settings. Closing clinical depth gap through MapEnhance partnerships.

vs. Definitive Healthcare

Definitive Healthcare competes narrowly in sales intelligence (provider directories, facility data, HCP targeting). Lacks longitudinal patient journey data and HEOR/regulatory evidence capability. Komodo’s Aperture and Iris directly address Definitive’s use cases with the advantage of actual patient journey data grounding.

Recent Developments

• Marmot AI Launch (August 2025): Flagship healthcare-native AI engine trained on 1M+ active cohorts.
• Healthcare Map on Snowflake Marketplace (October 2025): Distribution expansion to non-traditional customers.
• Helix Partnership (January 2025): Clinico-genomic data from 500,000+ whole-exome profiles — first germline genomic dataset partner.
• Nasdaq Partnership (May 2025): Healthcare data for financial services (hedge funds, PE, VC). Revenue diversification.
• Anervea.ai Partnership (July 2025): First third-party developer on MapLab Enterprise, establishing ecosystem/marketplace strategy.
• Drug Projections Launch (2024): Real-time market intelligence on 10,000+ therapies.
• Leadership Additions: Miles Ennis (COO/CRO from Cisco/IBM, 2024), Paul Thomas (Acting CFO from Talkdesk/Sumo Logic, 2025), Mark Jewett (CMO from Tableau/Microsoft, 2025) — signaling IPO readiness.

Financial Profile

Total disclosed funding: ~$514M. Key rounds: Series C ($50M, January 2020, Felicis Ventures), Series E ($220M, March 2021, Tiger Global/Casdin Capital, $3.3B valuation), Structured Equity ($200M, November 2022, Coatue Management). Early investors include Andreessen Horowitz.

As of 2022: ARR ~$150M with >50% YoY growth and “SaaS-like margins” (not yet profitable). No more recent revenue disclosed. Business model: enterprise SaaS subscriptions + data licensing (Snowflake, Nasdaq NMCI) + analytics services. IPO readiness signaled but no formal filing.

Sources

Primary source: raw/research/05_komodo_health.md. Data from Contrary Research, Komodo Health press releases, PLOS ONE (Janssen validation study), Frost & Sullivan, Helix, IntuitionLabs.